Generex Biotechnology Corporation (NASDAQ:GNBT) announced it has received two new patents for its 
proprietary buccal drug delivery system in Japan and Ukraine. These patents will cover the company’s methods of preparation and administration and open up other marketplaces for GNBT.
After this announcement was made, Generex’s shares rose up 5.47% and the market cap became 106.99M. Yesterday the stock closed at $0.42 with total volume of 4.27 million traded shares.
Though Generex Biotechnology Corp. has lost over 11% during the past month, it is currently trading above its 20-day and below its 50-day moving averages.
The company’s financials show that its revenue and net income for 2009 are higher compared to 2008, and the employee growth points 59.3%.
This year GNBT expects the new patents will bring higher profit to its business. At the company’s official website, Generex publishes the news on its projects, as well as a letter to the shareholders with all the information on GNBT’s products and approvals.
